These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 34740186)

  • 1. Stereotactic radiosurgery for glioblastoma considering tumor genetic profiles: an international multicenter study.
    Bunevicius A; Pikis S; Kondziolka D; Patel DN; Bernstein K; Sulman EP; Lee CC; Yang HC; Delabar V; Mathieu D; Cifarelli CP; Arsanious DE; Dahshan BA; Weir JS; Speckter H; Mota A; Tripathi M; Kumar N; Warnick RE; Sheehan JP
    J Neurosurg; 2022 Jul; 137(1):42-50. PubMed ID: 34740186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stereotactic radiosurgery for IDH wild type glioblastoma: an international, multicenter study.
    Bunevicius A; Pikis S; Kondziolka D; Patel DN; Bernstein K; Sulman EP; Lee CC; Yang HC; Delabar V; Mathieu D; Cifarelli CP; Arsanious DE; Dahshan BA; Weir JS; Speckter H; Mota A; Tripathi M; Kumar N; Warnick RE; Peker S; Samanci Y; Barnett G; Hefnawi FE; Al Sideiri G; Sheehan J
    J Neurooncol; 2021 Dec; 155(3):343-351. PubMed ID: 34797526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes and prognostic stratification of patients with recurrent glioblastoma treated with salvage stereotactic radiosurgery.
    Sharma M; Schroeder JL; Elson P; Meola A; Barnett GH; Vogelbaum MA; Suh JH; Chao ST; Mohammadi AM; Stevens GHJ; Murphy ES; Angelov L
    J Neurosurg; 2018 Oct; 131(2):489-499. PubMed ID: 30485180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of adjuvant or salvage radiosurgery in the management of unresected residual or progressive glioblastoma multiforme in the pre-bevacizumab era.
    Niranjan A; Kano H; Iyer A; Kondziolka D; Flickinger JC; Lunsford LD
    J Neurosurg; 2015 Apr; 122(4):757-65. PubMed ID: 25594327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stereotactic radiosurgery for intracranial hemangiopericytomas: a multicenter study.
    Cohen-Inbar O; Lee CC; Mousavi SH; Kano H; Mathieu D; Meola A; Nakaji P; Honea N; Johnson M; Abbassy M; Mohammadi AM; Silva D; Yang HC; Grills I; Kondziolka D; Barnett GH; Lunsford LD; Sheehan J
    J Neurosurg; 2017 Mar; 126(3):744-754. PubMed ID: 27104850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic alterations predictive of response to radiosurgery in recurrent IDH-WT glioblastoma.
    Dono A; Amsbaugh M; Martir M; Smilie RH; Riascos RF; Zhu JJ; Hsu S; Kim DH; Tandon N; Ballester LY; Blanco AI; Esquenazi Y
    J Neurooncol; 2021 Mar; 152(1):153-162. PubMed ID: 33492602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. O
    Alassiri AH; Alkhaibary A; Al-Sarheed S; Alsufani F; Alharbi M; Alkhani A; Aloraidi A
    Ann Saudi Med; 2019; 39(6):410-416. PubMed ID: 31804140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Partial resection offers an overall survival benefit over biopsy in MGMT-unmethylated IDH-wildtype glioblastoma patients.
    Hallaert G; Pinson H; Vanhauwaert D; Van den Broecke C; Van Roost D; Boterberg T; Kalala JP
    Surg Oncol; 2020 Dec; 35():515-519. PubMed ID: 33152608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of
    Lam K; Eldred BSC; Kevan B; Pianka S; Eldred BA; Zapanta Rinonos S; Yong WH; Liau LM; Nghiemphu PL; Cloughesy TF; Green RM; Lai A
    Neurooncol Adv; 2022; 4(1):vdac030. PubMed ID: 35386566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive value of MGMT promoter methylation on the survival of TMZ treated
    Chai R; Li G; Liu Y; Zhang K; Zhao Z; Wu F; Chang Y; Pang B; Li J; Li Y; Jiang T; Wang Y
    Cancer Biol Med; 2021 Feb; 18(1):272-282. PubMed ID: 33628600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma.
    Molinaro AM; Hervey-Jumper S; Morshed RA; Young J; Han SJ; Chunduru P; Zhang Y; Phillips JJ; Shai A; Lafontaine M; Crane J; Chandra A; Flanigan P; Jahangiri A; Cioffi G; Ostrom Q; Anderson JE; Badve C; Barnholtz-Sloan J; Sloan AE; Erickson BJ; Decker PA; Kosel ML; LaChance D; Eckel-Passow J; Jenkins R; Villanueva-Meyer J; Rice T; Wrensch M; Wiencke JK; Oberheim Bush NA; Taylor J; Butowski N; Prados M; Clarke J; Chang S; Chang E; Aghi M; Theodosopoulos P; McDermott M; Berger MS
    JAMA Oncol; 2020 Apr; 6(4):495-503. PubMed ID: 32027343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Telomerase reverse transcriptase promoter mutation- and O
    Gramatzki D; Felsberg J; Hentschel B; Wolter M; Schackert G; Westphal M; Regli L; Thon N; Tatagiba M; Wick W; Schlegel U; Krex D; Matschke J; Roth P; Suresh MP; Kamp MA; Rushing EJ; Pietsch T; von Deimling A; Sabel M; Loeffler M; Weller M; Reifenberger G
    Eur J Cancer; 2021 Apr; 147():84-94. PubMed ID: 33631540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MGMT promoter methylation status as a prognostic factor for the outcome of gamma knife radiosurgery for recurrent glioblastoma.
    Kim BS; Kong DS; Seol HJ; Nam DH; Lee JI
    J Neurooncol; 2017 Jul; 133(3):615-622. PubMed ID: 28536992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation and isocitrate dehydrogenase-1 (IDH-1) mutation in glioblastoma multiforme patients: A single-center experience in the Middle East region.
    Ayoub Z; Geara F; Najjar M; Comair Y; Khoueiry-Zgheib N; Khoueiry P; Mahfouz R; Boulos FI; Kamar FG; Andraos T; Saadeh F; Kreidieh F; Abboud M; Skaf G; Assi HI
    Clin Neurol Neurosurg; 2019 Jul; 182():92-97. PubMed ID: 31108342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Levetiracetam Use Duration on Overall Survival of Isocitrate Dehydrogenase Wild-Type Glioblastoma in Adults: An Observational Study.
    Pallud J; Huberfeld G; Dezamis E; Peeters S; Moiraghi A; Gavaret M; Guinard E; Dhermain F; Varlet P; Oppenheim C; Chrétien F; Roux A; Zanello M
    Neurology; 2022 Jan; 98(2):e125-e140. PubMed ID: 34675100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Arterial spin labeling perfusion-weighted imaging aids in prediction of molecular biomarkers and survival in glioblastomas.
    Yoo RE; Yun TJ; Hwang I; Hong EK; Kang KM; Choi SH; Park CK; Won JK; Kim JH; Sohn CH
    Eur Radiol; 2020 Feb; 30(2):1202-1211. PubMed ID: 31468161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The predictive value of partial
    Torre M; Wen PY; Iorgulescu JB
    Neurooncol Pract; 2023 Apr; 10(2):126-131. PubMed ID: 36970171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stereotactic radiosurgery for treatment of radiation-induced meningiomas: a multiinstitutional study.
    Bunevicius A; Suleiman M; Patel S; Martínez Álvarez R; Martinez Moreno NE; Liscak R; Hanuska J; Langlois AM; Mathieu D; Mau C; Caldwell C; Tuanquin LC; Zacharia BE; McInerney J; Lee CC; Yang HC; Peterson JL; Trifiletti DM; Ogino A; Kano H; Warnick RE; Saylany A; Buch LY; Lee JYK; Strickland BA; Zada G; Chang EL; Lunsford LD; Sheehan J
    J Neurosurg; 2021 Jan; 135(3):862-870. PubMed ID: 33385995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of MGMT Promoter Methylation With Survival in Low-grade and Anaplastic Gliomas After Alkylating Chemotherapy.
    Kinslow CJ; Mercurio A; Kumar P; Rae AI; Siegelin MD; Grinband J; Taparra K; Upadhyayula PS; McKhann GM; Sisti MB; Bruce JN; Canoll PD; Iwamoto FM; Kachnic LA; Yu JB; Cheng SK; Wang TJC
    JAMA Oncol; 2023 Jul; 9(7):919-927. PubMed ID: 37200021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma.
    SongTao Q; Lei Y; Si G; YanQing D; HuiXia H; XueLin Z; LanXiao W; Fei Y
    Cancer Sci; 2012 Feb; 103(2):269-73. PubMed ID: 22034964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.